Sign In
Last checked at 
2 Apr 2012 17:21
ο»Ώ
Β
Β
Β
Β
Β
Hikma Pharmaceuticals PLC - Voting Rights and Capital
Β
LONDON, 2 April 2012 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 March 2012 its capital consists of 196,806,607 ordinary shares with voting rights. There are no shares held in treasury.
Β
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.
Β
- ENDS -
Β
Enquiries:
Β
Hikma Pharmaceuticals PLC | Β |
Peter Speirs Deputy Company Secretary Β | +44 20 7399 2760 Β |
Β
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and nonβbranded generic and inβlicensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.
Β
Follow the stocks
